With New Launch, Pathway Genomics Claims First to Offer Liquid Biopsy Test for Early Cancer Detection | GenomeWeb

NEW YORK (GenomeWeb) – Pathway Genomics on Thursday launched the first liquid biopsy test, called CancerIntercept Detect, aimed at the early discovery of malignancies in asymptomatic people with an elevated risk of developing cancer.

Though leaders in the liquid biopsy research field have said they are still waiting for the first demonstration of a technology's ability to detect cancer in undiagnosed patients with the appropriate clinical sensitivity and without a high rate of false positives, Pathway believes its platform has the ability to meet the appropriate threshold.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.

Arizona is planning to sue Theranos for "deceptive acts" and misrepresentations of its "capabilities and operation."

If confirmed as Department of Health and Human Services Secretary, Tom Price says he will divest himself of certain holdings, according to Stat News.

Oliver Smithies, who won the Nobel Prize in 2007, has died, the New York Times reports.